Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
- Valbenazine Met the Primary Endpoint of Significant (p<0.0001) Improvement in Chorea Severity versus Placebo as Measured by the Unified Huntingtons Disease...
United States Eiryw Roberts Neurocrine Biosciences Huntington Study Group American Academy Of Neurology Drug Administration
Source: prnewswire.com